ten years of work with the very large team across several institutions. but it is very significant because as you mentioned, this is a technology that will benefit patients with very rare blood groups that are otherwise very difficult to transfused, because we simply cannot find blood donors that match them to treat them in hospital. 50 match them to treat them in hosital. ,., ., match them to treat them in hosital. ., ., , hospital. so some of that blood has been uiven hospital. so some of that blood has been given to hospital. so some of that blood has been given to people, hospital. so some of that blood has been given to people, this - hospital. so some of that blood has been given to people, this is - hospital. so some of that blood has been given to people, this is the i been given to people, this is the first time that has happened, so what can you tell us about that? what are we doing at the moment is a micro dosing study. we are only giving two spoonfuls of red cells that
it is a very significant development. these technologies that are coming out of academic research need to be translated into human studies. in reaching that point is the result of ten years of work with the very large team across several institutions. but it is very significant because as you mentioned, this is a technology that will benefit patients with very rare blood groups that are otherwise very difficult to transfused, because we simply cannot find blood donors that match them to treat them in hospital. so some of that blood has been given to people, this is the first time that has happened, so what can you tell us about that? what are we doing at the moment is a micro dosing study. we are only giving two spoonfuls of red cells that have developed in the lab and relabel them. after the infusion into healthy volunteers, we can actually track how long they survive and that will tell us whether they actually survive just as well and will be better than the standard red cells we der